Novo Nordisk A/S (NVO)’s share was trading at $67.74 as of May 12th. NVO’s trailing and forward P/E were 19.18 and 16.50 respectively according to Yahoo Finance.

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster GLP-1 drugs. But it won't end all compounding offerings.

Novo Nordisk's GLP-1 Market Growth (Novo Nordisk's Q1-2025 Investor Presentation) The next risk is drug pricing reform in the US, as it could pressure margins.

Similar to Novo Nordisk, Eli Lilly's growth mostly stemmed from obesity and GLP-1 drugs. In the case of Novo Nordisk, it is Ozempic and Wegovy, which is driving growth, in case of Eli Lilly, it is ...